Vol 43 # 2 June 2011 - Kma.org.kw

96
The Knowledge of Teratogenicity in the Prevention of Congenital Anomalies
June 2011
8. Chittaranjan A. Teratogenicty and hyperprolactinemia.
Indian J Psychiatry 2009; 51:62-64.
9. Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S,
Diav-Citrin O. The outcome of pregnancy following
topiramate treatment: a study on 52 pregnancies. Reprod
Toxicol 2008; 25:388-389.
10. Influences on prenatal development. (Accessed July 5,
2010 at http://www.saskschools.ca/ www.nas.com)
11. Robson JM. Testing drugs for teratogenicity and their
effects on fertility. Brit Med Bull 1970: 212-216.
12. Teratogens. (Accessed July 5, 2010 at http://www.
safetyemporium.com)
13. Orna Diav-Citrin, Gideon Koren. Human Teratogens: a
critical evaluation. The Motherisk Program, the Hospital
for Sick Children, Toronto, Ontario, Canada 2008.
14. Wilson JG. Present status of drugs as teratogens in man.
Teratology 1973; 7:3-15.
15. Shepard TH. Teratogenicity of therapeutic agents. Curr
Probl Pediatr 1979; 10:1-42.
16. Teratology Society Public Affairs Committee. FDA
classification of drugs for teratogenic risk. Teratology
1994; 49:446-447.
17. German J, Kowal A, Ehlers KH. Trimethadione and
human teratogenesis. Teratology 1970; 3:349-362.
18. Bellinger DC. Teratogen update: lead and pregnancy.
Birth Defects Res A Clin Mol Teratol 2005; 73:409-420.
19. Goel RK, Prabha T, Kumar MM, Dorababu M, Prakash
G, Singh G. Teratogenicity of Asparagus racemosus wild
root, a herbal medicine. Indian J Exp Biol 2006; 44:570-
573.
20. Paz R, Barsness B, Martenson T, Tanner D, Allan AM.
Behavioral teratogenicity induced by non-forced maternal
nicotine consumption. Neuropsychopharmacology 2007;
32:693-699.
21. Mobarak YM. Embryotoxicity and teratogenicity of
enrofloxacin on maternally treated chick. Asian J Dev
Biol 2010; 2:1-15.
22. Adebisi SS. The toxicity of artesunate on bone
development: the Wistar rat animal model of malaria
treatment. Internet Journal of Parasitic Diseases 2009.
(Accessed March 10, 2010 at http://www.ispub.com/
journal)
23. Adebisi SS. Assessment of the effect of artesunate on the
developing bones of Wistar rat animal model of malaria
treatment. TAF Prev Med Bull 2010; 9:23-28.
24. Kotwani A, Mehta VL, Gupta U, Prabhu S, Bafna JS.
Methods for teratogenicity testing – existing and future
models. Indian J Pharmacol 1995; 27:204-213.
25. Hindin R, Brugge D, Panikkar B. An epidemiological
perspective on the teratogenicity of depleted uranium
aerosols. Environmental Health: A Global Access Science
Source 2005; 4:17.
26. Bromocriptine – Teratogenic agent. (Accessed July 6, 2010
at http://www.wrongdiagnosis.com/b/bromocriptine
teratogenic agent/intro.htm)
27. Francella A, Dayan A, Rubin P, Chapman M, Present
D. 6-Mercaptopurine is a safe therapy for child bearing
patients with inflammatory bowel disease. a case
controlled study. Gastroenterology 1996; 110: A 909.
28. Beasley V. Teratogenic agents. Veterinary Toxicology.
Document A2621.0899. (Accessed July 5, 2010 at http://
www.ivis.org/advances/Beasley/Cpt8a/IVIS.pdf)
29. Chung W. Teratogens and their effects. (Accessed March
10, 2010 at http://www.wkc.columbia.edu)
30. Wilson JG. Present status of drugs as teratogens in man.
Teratology 1973; 7:3-15.
31. Teratogenicity Psychology. (Accessed July 6, 2010 at
http://www.wikipedia.org)
32. Birth defects - drugs and medications. Health and
medical information for consumers. Australia. (Accessed
March 10, 2010 at http://www.betterhealthchannel.
com)
33. Rockenbauer M, Olsen J, Czeizel AE, Pedersen L,
Sorensen HT. Recall bias in a case-control surveillance
system on the use of medicine during pregnancy.
Epidemiology 2001; 12:461-466.
34. Czeizel AE, Petik D, Vargha P. Validation studies of drug
exposures in pregnant women. Pharmacoepid Drug
Safety 2003; 12:409-416.
35 Czeizel AE. Drug exposure in pregnant women. Lupus
2004; 13:740-745.
36. van Gelder MM, van Rooji IA, Miller RK, Zielhuis
GA, de Jong-van den Berg LT, Roelveld N. Teratogenic
mechanism of medical drugs. Human Reproduction
Update 2010; 16:378-394.
37. 2004 Boston cure project for multiple sclerosis: a
framework for describing diseases caused by toxic agents.
(Accessed July 5, 2010 at http://www.bostoncure.org)
38. Brent RL. Environmental causes of human congenital
malformations: the pediatrician’s role in dealing with
these complex clinical problems caused by a multiplicity
of environmental and genetic factors. Pediatrics 2004;
113:957-968.
39. Moallem SA, Ahmadi A, Nyapour M, Hossini T, Habibi
G. Role of apoptosis in HESA-A teratogenicity in mice
fetus. Drug and Chemical Toxicology 2009; 32:186-190.
40. Mirkin BL, Singh S. Placental transfer of
pharmacologically active molecules. In: Mirkin BL,
editor. Perinatal Pharmacology and Therapeutics, New
York: New York Academic Press; 1976. p 1-69.
41. Waddell WJ, Marlowe GC. Disposition of drugs in the
fetuses. In: Mirkin BL, editor. Perinatal Pharmacology
and Therapeutics, New York: New York Academic
Press; 1976. p 119-268.
42. Miller RK, Davis BM, Brent RL, Koszalka TR. Creatine
transport by rat placentas. Am J Physiol 1977; 233: E308-
E315.
43. Wilson JG, Scott WJ, Ritter EJ, Fradklin R. Comparative
distribution and embryotoxicity of hydroxy urea in
pregnant rats and rhesus monkeys. Teratology 1979;
11:169-178.
44. Jones KL, Smith DW, Recognition of the fetal alcohol
syndrome. Lancet 1973; 2:999-1001.
45. Jones HM, Cunnings AJ. A study of the transfer of alphamethyl
dopa to the human fetuses and newborn infants.
Brit J Clin Pharm 1978;6: 432-434.
46. Danielsson BR, Danielson M, Reiland S , Rundqvist E,
Dencker L, Regard CG. Histological and in vitro studies
supporting decreased utero-placental blood flow as
explanation for digital defects after administration of
vasodilators. Teratology 1990; 41:185-193.
47. Hepper P. Prenatal Development. (Accessed march 2010,
at http://www.oup.com/uk/orc/bin/9780199283057/
slater_chap03.pdf)